LeMaitre Vascular (LMAT) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
14 Apr, 2026Executive summary
Annual meeting scheduled for June 2, 2026, at the company’s headquarters in Burlington, MA at 10:00 a.m. EDT.
Proxy materials and the 2025 Annual Report are available online for review and voting.
Shareholders are encouraged to vote online or request paper copies of proxy materials by May 22, 2026, for timely delivery.
Voting matters and shareholder proposals
Election of two directors: David B. Roberts and John A. Roush, with board recommendation to vote FOR both.
Advisory (non-binding) vote on 2025 executive compensation, with board recommendation to vote FOR.
Ratification of Grant Thornton LLP as independent auditor for fiscal year ending December 31, 2026, with board recommendation to vote FOR.
Board of directors and corporate governance
Board recommends approval of all proposals and nominees presented for the 2026 annual meeting.
Latest events from LeMaitre Vascular
- Q2 2026 saw double-digit sales and EPS growth, with strong margins and global expansion.LMAT
Q2 2026 - Q1 2026 saw 11% sales and 42% EPS growth, with raised guidance and strong biologics momentum.LMAT
Q1 2026 - Annual meeting to vote on directors, executive pay, and auditor, with focus on governance and performance.LMAT
Proxy filing - Double-digit growth, global expansion, and 15 years of dividend increases drive strong outlook.LMAT
Investor presentation - Q4 2025 saw 16% sales and 47% profit growth; 2026 outlook features strong growth and capital returns.LMAT
Q4 2025 - Q3 2024 sales up 16%, EPS up 49%, with raised guidance and strong biologics-driven growth.LMAT
Q3 2024 - Q2 net income up 46% on 11% sales growth; 2024 guidance raised for sales and EPS.LMAT
Q2 2024 - Q1 2025 saw 13% organic sales growth, margin gains, and a raised outlook amid global expansion.LMAT
Q1 2025 - Double-digit growth, margin gains, and higher shareholder returns drive 2025 outlook.LMAT
Q4 2024